文献速递临床试验与 GCP基础与转化研究流行病学与生物统计

评估早期外显子组测序在多样化儿科门诊人群中的临床效用:NCGENES 2 随机对照试验

Evaluating the clinical utility of early exome sequencing in diverse pediatric outpatient populations in the North Carolina Clinical Genomic Evaluation of Next-generation Exome Sequencing (NCGENES) 2 study: a randomized controlled trial.
PubMed 文献 · Trials · 2021-06-14

NCGENES 2 是一项跨学科、多中心 III 期随机对照试验,采用全因子设计评估就诊前教育准备(PVP)与一线外显子组测序(ES)两种干预。研究在 North Carolina 三家医疗机构的儿科遗传或神经门诊招募小于 16 岁、疑似遗传病且处于诊断旅程早期的患儿,并过采样服务不足和代表性不足人群。研究旨在评估早期诊断性 ES 对缩短诊断旅程的技术、临床、心理社会与卫生经济学价值,为政策、实践和未来研究提供证据。

要点

  • NCGENES 2 采用全因子随机对照设计,评估 PVP 与一线 ES 对儿科疑似遗传病患者的效用。
  • 研究对象为小于 16 岁、首次就诊儿科遗传或神经门诊且疑似遗传病的患儿。
  • 研究过采样服务不足和代表性不足人群,并设社区咨询团队参与。

核心结论

  • NCGENES 2 将生成关于早期诊断性 ES 用于缩短疑似遗传病儿科患者诊断旅程的技术、临床、心理社会与卫生经济学证据。
  • 研究结果可服务于多样化人群参与基因组医学研究,并为一线诊断性 ES 的效用相关政策、实践和未来研究提供依据。

研究设计与样本

  • NCGENES 2 是跨学科、多中心 III 期随机对照试验,采用全因子设计比较就诊前教育准备(PVP)与一线外显子组测序(ES)两种干预。
  • 亲子对按等比例随机分配至四个研究臂:PVP+常规照护、ES+常规照护、PVP+ES+常规照护、单独常规照护。
  • 参与者从 North Carolina 三家医疗机构的儿科遗传或神经门诊招募,纳入标准为小于 16 岁、首次就诊参与门诊、疑似遗传病且有合格家长/监护人陪同完成研究测量。
  • 研究过采样服务不足和代表性不足人群;随机分配至一线 ES 的结果在患儿门诊就诊后揭晓。

关键数值与推荐

  • 分配到 PVP 臂的参与者在线下临床互动前收到教育手册和问题提示列表。
  • 可报告的研究相关 ES 结果在 CLIA 认证的临床实验室确认,并由临床团队向家长披露。

临床怎么用

  • 早期诊断性 ES 若被证实有效,可作为缩短儿科疑似遗传病患者诊断旅程的常规临床工具。
  • 就诊前教育准备(PVP)可作为提升家长参与和知情决策的辅助干预。

局限性

  • 本文仅报告研究设计与方法,尚未提供 ES 临床效用的结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exome sequencing (ES) has probable utility for shortening the diagnostic odyssey of children with suspected genetic disorders. This report describes the design and methods of a study evaluating the potential of ES as a routine clinical tool for pediatric patients who have suspected genetic conditions and who are in the early stages of the diagnostic odyssey. METHODS: The North Carolina Clinical Genomic Evaluation by Next-generation Exome Sequencing (NCGENES) 2 study is an interdisciplinary, multi-site Phase III randomized controlled trial of two interventions: educational pre-visit preparation (PVP) and offer of first-line ES. In this full-factorial design, parent-child dyads are randomly assigned to one of four study arms (PVP + usual care, ES + usual care, PVP + ES + usual care, or usual care alone) in equal proportions. Participants are recruited from Pediatric Genetics or Neurology outpatient clinics in three North Carolina healthcare facilities. Eligible pediatric participants are < 16 years old and have a first visit to a participating clinic, a suspected genetic condition, and an eligible parent/guardian to attend the clinic visit and complete study measures. The study oversamples participants from underserved and under-represented populations. Participants assigned to the PVP arms receive an educational booklet and question prompt list before clinical interactions. Randomization to offer of first-line ES is revealed after a child's clinic visit. Parents complete measures at baseline, pre-clinic, post-clinic, and two follow-up timepoints. Study clinicians provide phenotypic data and complete measures after the clinic visit and after returning results. Reportable study-related research ES results are confirmed in a CLIA-certified clinical laboratory. Results are disclosed to the parent by the clinical team. A community consultation team contributed to the development of study materials and study implementation methods and remains engaged in the project. DISCUSSION: NCGENES 2 will contribute valuable knowledge concerning technical, clinical, psychosocial, and health economic issues associated with using early diagnostic ES to shorten the diagnostic odyssey of pediatric patients with likely genetic conditions. Results will inform efforts to engage diverse populations in genomic medicine research and generate evidence that can inform policy, practice, and future research related to the utility of first-line diagnostic ES in health care. TRIAL REGISTRATION: ClinicalTrials.gov NCT03548779 . Registered on June 07, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Staley BS, Milko LV, Waltz M, et al. Evaluating the clinical utility of early exome sequencing in diverse pediatric outpatient populations in the North Carolina Clinical Genomic Evaluation of Next-generation Exome Sequencing (NCGENES) 2 study: a randomized controlled trial. Trials. 2021. PMID: 34127041. doi:10.1186/s13063-021-05341-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。